{"filings":[{"id":91199,"accession_number":"0001087294-26-000046","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cumberland Pharma enters $100M strategic transaction with Apotex, reports Q1 revenue $9.1M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Entered $100M cash deal to sell FDA-approved brand portfolio to Apotex Inc.; subject to shareholder approval and closing conditions.","Q1 net revenue $9.1M (+5% ex-$3M prior-year milestone); net loss $3.3M; adjusted loss $0.13/share.","FDA granted Fast Track Designation for ifetroban in Duchenne Muscular Dystrophy; Phase II study showed breakthrough results.","Ended quarter with $11M cash, $5.2M drawn on credit facility, total assets $71M, equity $21.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91198,"accession_number":"0001087294-26-000043","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cumberland shareholders elect two Class I directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Kenneth J. Krogulski elected with 99.52% votes in favor; Caroline R. Young with 98.66%.","Ratification of Carr, Riggs & Ingram as auditor for FY 2026 received 99.82% approval.","Advisory vote on executive compensation passed with 99.82% votes in favor.","Frequency vote: every three years for say-on-pay received 7,844,848 votes vs 1,733,309 for every year.","All proposals passed; annual meeting held April 21, 2026 in Nashville, Tennessee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91197,"accession_number":"0001104659-26-047335","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Cumberland Pharma sells commercial products to Apotex for $100M, retains pipeline","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Apotex acquires six FDA-approved brands (Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ) for $100M cash.","Cumberland retains ifetroban pipeline (DMD, SSc, IPF) and majority stake in CETI.","Deal requires shareholder approval; directors & officers holding ≈41% of shares signed voting agreements to support.","Either party may owe $4M termination fee under conditions; closing targeted by August 20, 2026.","Board and financial advisor VelocityHealth opined $100M consideration fair and reasonable to Cumberland."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101158,"accession_number":"0001087294-26-000015","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cumberland Pharma reports Q4 revenue up 31% to $13.7M; full-year adjusted earnings $1.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 net revenue $44.5M (+18% YoY); net loss improved to $2.9M from $6.5M.","Adjusted earnings for 2025 were $1.7M vs. -$1.0M in 2024; operating cash flow $4.9M.","Debt reduced by $10M; credit facility balance $5.2M at year-end; shareholders equity $24.9M.","Vibativ approved in China; launched in Saudi Arabia; Talicia co-commercialization began Oct 2025.","Caldolor received permanent J-code (J1741) for CMS reimbursement in Dec 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101157,"accession_number":"0001087294-26-000011","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cumberland Pharma gets FDA Fast Track for ifetroban in DMD heart disease","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA Fast Track Designation granted for ifetroban targeting fatal heart disease in Duchenne muscular dystrophy.","Designation follows previous Orphan Drug and Rare Pediatric Disease Designations for same indication.","Phase 2 FIGHT DMD trial showed 5.4% improvement in left ventricular ejection fraction over 12 months.","Fast Track enables expedited review, rolling submission, and more frequent FDA interactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117507,"accession_number":"0001087294-25-000023","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Cumberland amends credit line: reduces revolver to $15M, extends maturity to Oct 2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal available reduced to $15M (from $20M); right to request additional $10M (up from $5M).","Maturity extended to October 1, 2027; interest rate is Benchmark Term SOFR + 2.75%.","New financial covenant: Minimum Fixed Charge Coverage Ratio of 1.75x, replacing Maximum Funded Debt Ratio.","Borrowing Base Requirements made permanent; company paid $15,000 amendment fee.","Collateral remains substantially all assets; credit line with Pinnacle Bank."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117506,"accession_number":"0001087294-25-000017","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cumberland Pharma reports Q3 net loss of $1.9M; YTD revenue up 12% to $30.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue for Q3 2025 was $8.3M; YTD $30.8M (+12% vs. 2024).","Net loss Q3 $1.9M; YTD net loss $1.4M. Adjusted loss Q3 $0.8M ($0.06/sh); adjusted earnings YTD $1.9M ($0.13/sh).","Added Talicia via joint venture with RedHill: Cumberland invests $4M for 30% ownership; net revenue split equally.","Vibativ launched in Saudi Arabia; ibuprofen injection approved in Mexico; Vibativ available through Vizient.","Ifetroban Phase II DMD showed 5.4% cardiac improvement; Phase II SSc enrollment complete; IPF trial enrolling."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":30842780.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117505,"accession_number":"0001087294-25-000012","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cumberland Pharmaceuticals forms joint venture with RedHill to commercialize Talicia H. pylori therapy","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cumberland and RedHill form new jointly owned company; Cumberland provides $4M in investment capital.","RedHill contributes all Talicia assets; Cumberland handles distribution and records product sales.","Talicia generated $8M net revenue in 2024; both companies equally share net revenues.","Talicia is FDA-approved for H. pylori, patent protected through 2042, with QIDP exclusivity.","Product has broad insurance coverage: 70% commercial, 60% government; CVS stocks at 1,700 pharmacies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133919,"accession_number":"0001628280-25-037923","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cumberland Pharma reports Q2 revenue up 10% YoY; YTD revenue +23%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net revenue $10.8M (+10% YoY); YTD net revenue $22.6M (+23%).","Q2 net loss $741k; YTD net income $516k; adjusted YTD EPS $0.18.","Ifetroban Phase II DMD trial showed 5.4% improvement in cardiac function; FDA submission completed.","Vibativ 4-vial starter pak now available via Vizient, covering >65% of U.S. acute care providers.","Cash and equivalents $16M; total assets $68M; shareholders' equity $28M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":22550418.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150663,"accession_number":"0001628280-25-022753","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cumberland Q1 revenue $11.7M (+38% YoY), net profit $1.3M; DMD Phase II positive, Vibativ China OK","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $11.7M vs $8.5M prior year, 38% increase.","Net income $1.3M; adjusted earnings $2.4M ($0.16/shr); operating cash flow $3.9M.","Positive Phase II data for ifetroban in Duchenne muscular dystrophy; FDA end-of-phase-II meeting planned.","Vibativ approved in China; launch expected by end of 2025.","Balance sheet: $15.1M cash, $5.2M drawn on credit facility; equity $28.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":11713055.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150662,"accession_number":"0001628280-25-020222","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cumberland shareholders re-elect three directors, ratify auditor with >98% votes","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors Bernard, Galante, and Kazimi re-elected with 98.6%, 99.2%, and 99.6% votes in favor.","Auditor Carr, Riggs & Ingram ratified for 2025 with 99.7% votes in favor.","Annual meeting held April 22, 2025 in Nashville, Tennessee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169613,"accession_number":"0001628280-25-013875","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cumberland's ifetroban shows 5.4% cardiac improvement in DMD Phase 2 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["High-dose ifetroban improved LVEF by 3.3% vs. placebo and 5.4% vs. natural history controls.","Results from FIGHT DMD trial selected for late-breaking presentation at MDA Clinical & Scientific Conference.","Ifetroban has FDA Orphan Drug and Rare Pediatric Disease Designations for DMD heart disease.","End-of-Phase-2 meeting with FDA planned to discuss next steps for development and commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169612,"accession_number":"0001628280-25-009967","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cumberland Pharma Q4 revenue +11.6% to $10.4M; full-year net loss $6.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net revenue $10.4M, up 11.6% YoY; full-year revenue $38M.","Full-year net loss $6.4M; adjusted loss $1.0M (excl. $1.3M product acquisition costs).","Cash $18M, total assets $76M, liabilities $53M, shareholders' equity $23M at year-end.","Phase 2 ifetroban DMD study positive top-line; Vibativ approved in China.","Kristalose $15.3M, Sancuso $9M, Vibativ $7.2M, Caldolor $5M in 2024 revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169611,"accession_number":"0001628280-25-006430","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cumberland gets NMPA approval in China for Vibativ; exclusive deal with SciClone","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Vibativ (telavancin) approved by China's NMPA for hospital-acquired pneumonia, ventilator-associated pneumonia, and complicated skin infections.","SciClone granted exclusive rights to register, promote, and distribute Vibativ in China.","Companies plan to launch Vibativ in China later in 2025.","Vibativ is a once-daily IV antibiotic designed to treat multidrug-resistant Gram-positive bacteria."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169610,"accession_number":"0001628280-25-005744","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cumberland Pharmaceuticals increases ATM offering size to $10M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Maximum aggregate offering price under Sales Agreement with H.C. Wainwright raised to $10,000,000.","Prospectus supplement filed February 14, 2025, amending prior $0 limit or undisclosed prior cap.","Shares of common stock (CPIX) may be sold at-the-market from time to time.","No specific use of proceeds stated in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169609,"accession_number":"0001628280-25-003753","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cumberland Pharma Phase 2 ifetroban trial meets primary endpoint in DMD heart disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["High-dose ifetroban (300mg/day) produced 3.3% LVEF improvement vs placebo decline of 1.5%, net 4.8% benefit.","Comparison with propensity-matched natural history controls showed 5.4% overall LVEF improvement in high-dose group.","Both doses were well-tolerated; no serious drug-related events reported among 41 enrolled DMD patients.","Ifetroban holds FDA Orphan Drug and Rare Pediatric Disease Designations; first Phase 2 study for DMD heart disease.","Company plans end of Phase 2 FDA meeting to discuss development path; potential first therapy for DMD cardiomyopathy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186675,"accession_number":"0001628280-24-050499","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA approves simplified dosing regimen for Cumberland's Acetadote IV NAC","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved sNDA for Acetadote on Dec 9, 2024; new regimen combines first two bags into a single slower infusion.","New dosing aims to reduce medication errors and non-allergic anaphylactoid reactions (NAARs) without compromising efficacy.","Acetadote indicated to prevent/lessen liver injury after acetaminophen overdose, the leading cause of acute liver failure in the US.","Cumberland Pharmaceuticals (CPIX) specialty pharma; CEO A.J. Kazimi highlighted commitment to improving patient care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186674,"accession_number":"0001628280-24-046827","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cumberland Pharma receives FDA Orphan Drug and Rare Pediatric Disease designations for Ifetroban in DMD","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Orphan Drug and Rare Pediatric Disease Designations to Ifetroban for cardiomyopathy associated with Duchenne muscular dystrophy.","Cumberland is completing the FIGHT DMD Phase II trial; results expected later in 2024.","Rare Pediatric Disease Designation may qualify company for a priority review voucher upon approval.","Orphan Drug Designation provides seven-year market exclusivity, tax credits, and fee waivers if approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186673,"accession_number":"0001628280-24-046399","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cumberland Pharma Q3 net loss $1.5M; Caldolor study, DMD designations announced","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 net revenue $9.1M; net loss $1.5M ($0.11 loss per share); adjusted loss $0.26M ($0.02 per share).","Real-world study of 150k patients shows Caldolor associated with fewer adverse drug reactions vs ketorolac.","FDA grants Orphan Drug and Rare Pediatric Disease designations for ifetroban in Duchenne Muscular Dystrophy.","Kristalose added to Medicaid plans in VA, LA, ME; Vibativ partner in Saudi Arabia begins ordering for launch.","Phase II MENDING trial for delirium meets primary safety endpoint; CET plans pivotal study discussion with FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":27432376.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186672,"accession_number":"0001628280-24-045807","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cumberland announces study showing Caldolor reduces adverse drug reactions vs ketorolac","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study analyzed records of >17M patients; compared 31,046 Caldolor vs 124,184 ketorolac adults.","Caldolor associated with 45% reduction in renal dysfunction (p<0.001) and 78% fewer hematuria events.","In pediatric patients, Caldolor showed 51-65% lower rate of adverse drug reactions.","Caldolor also linked to decreased ER visits and shorter hospital stay for both adults and children."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186671,"accession_number":"0001628280-24-045054","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CMS denies Caldolor separate Medicare reimbursement under NOPAIN Act for CY2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS excluded Caldolor from NOPAIN Act separate payment list announced Nov 1, 2024 for CY2025.","CMS concluded Caldolor does not qualify because FDA indication lacks mention of post-operative use.","Company submitted comments in July 2023 and July 2024 arguing Caldolor meets statutory requirements.","Company says majority of Caldolor use is surgical and FDA approval based on post-surgical pain studies.","Cumberland is evaluating options; calls CMS determination inconsistent with NOPAIN Act intent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203236,"accession_number":"0001628280-24-035262","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cumberland Pharma Q2 revenue $9.9M, up 16% sequentially; adjusted earnings positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net revenue $9.9M, 16% increase from Q1 2024; year-to-date $18.3M.","Adjusted earnings $0.2M ($0.01/share), a $0.8M improvement vs prior Q1 period.","Net loss $1.1M ($0.08/share) in Q2; year-to-date net loss $3.0M ($0.21/share).","Product revenue: Kristalose $4.1M, Vibativ $2.5M, Sancuso $2.2M, Caldolor $0.8M in Q2.","Cash $17.3M; $16.1M drawn on credit line; total assets $78.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":18346550.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219566,"accession_number":"0001628280-24-021185","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cumberland Pharmaceuticals Q1 net loss $1.9M; revenue $8.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $8.5M; Kristalose $3.2M, Sancuso $1.8M, Vibativ $1.6M, Caldolor $1.5M.","Net loss $1.9M ($0.14/share); adjusted loss $0.6M ($0.05/share).","Cash $19M, total assets $82M, liabilities $54M, equity $27M.","Caldolor highlighted in NOPAIN Act; CMS decision pending for 2025 Medicare reimbursement.","Ifetroban enrollment underway for Idiopathic Pulmonary Fibrosis trial (128 patients)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":8497701.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219565,"accession_number":"0001628280-24-019053","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cumberland Pharmaceuticals shareholders re-elect directors, ratify auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Martin S. Brown, Jr. re-elected as Class II director with 96.0% of votes in favor (8,544,756 for, 352,239 withheld).","James R. Jones re-elected as Class II director with 94.5% of votes in favor (8,411,468 for, 485,527 withheld).","Ratification of Carr, Riggs & Ingram LLC as auditor for FY2024 passed with 99.9% of votes in favor (11,189,440 for, 15,502 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":87801009.67071058,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}